1. Home
  2. SGRY vs GLPG Comparison

SGRY vs GLPG Comparison

Compare SGRY & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Surgery Partners Inc.

SGRY

Surgery Partners Inc.

HOLD

Current Price

$17.19

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Logo Galapagos NV

GLPG

Galapagos NV

HOLD

Current Price

$31.65

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SGRY
GLPG
Founded
2004
1999
Country
United States
Belgium
Employees
N/A
N/A
Industry
Hospital/Nursing Management
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.1B
IPO Year
2015
2005

Fundamental Metrics

Financial Performance
Metric
SGRY
GLPG
Price
$17.19
$31.65
Analyst Decision
Buy
Hold
Analyst Count
9
4
Target Price
$27.44
$31.33
AVG Volume (30 Days)
2.6M
125.8K
Earning Date
11-10-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,288,100,000.00
$336,643,201.00
Revenue This Year
$7.76
$3.61
Revenue Next Year
$8.16
N/A
P/E Ratio
N/A
N/A
Revenue Growth
10.14
10.31
52 Week Low
$14.94
$22.36
52 Week High
$26.16
$37.78

Technical Indicators

Market Signals
Indicator
SGRY
GLPG
Relative Strength Index (RSI) 44.19 50.15
Support Level $16.71 $30.97
Resistance Level $17.44 $31.98
Average True Range (ATR) 0.63 0.56
MACD 0.30 0.15
Stochastic Oscillator 89.29 75.41

Price Performance

Historical Comparison
SGRY
GLPG

About SGRY Surgery Partners Inc.

Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earns revenues from contracts with patients in which the performance obligations are to provide health care services.

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Share on Social Networks: